Omnipaque 300 (iohexol) is used as a medical contrast agent applied across domains where additional symptomatic support is needed by providing clear, detailed images for diagnostic purposes. The agent is considered relevant in procedures that help clinicians assess conditions involving various organ systems, which is generally an important part of patient assessment. This agent supports the diagnostic process, which is relevant in contexts involving heightened systemic burden. It is commonly used for procedures involving the central nervous system, detailed cardiovascular and vascular assessments, and for specialized joint and body cavity procedures.

“This agent may assist with maintaining functional stability.”

---

Main Uses and Benefits

Omnipaque 300 is applicable in clinical settings that involve acute or unstable symptom patterns. It helps address symptoms that interfere with daily functioning across multiple condition categories, including those marked by episodic or fluctuating manifestations. The agent's role is to support clearer imaging when symptoms become momentarily overwhelming, enabling doctors to identify issues causing symptoms linked to organ-specific functional stress. This overall support contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Support for Symptom Management

Regulatory References

1. NIH DailyMed Iohexol Labeling

Who Can and Cannot Use Omnipaque 300 (iohexol)?

Official regulatory documents define the strict eligibility criteria for using Omnipaque 300, focusing on specific patient populations and pre-existing conditions.

---

Absolute Contraindications

Omnipaque 300 must not be used if a patient has a known, serious hypersensitivity reaction to iohexol or any of its components, or if they have manifest thyrotoxicosis (severe, untreated hyperthyroidism). For procedures involving the spine (myelography), the agent is contraindicated in patients with homocystinuria due to the increased risk of seizures. Additionally, use for hysterosalpingography is contraindicated if the patient is pregnant.

---

Conditional Use and Restrictions

• Organ Function: Patients with severe renal impairment require conditional use and adequate hydration to manage eligibility. Dual hepatic and renal impairment may be an absolute contraindication in some regions.
• Age: The agent is approved for use in adults and children, including neonates. However, specific procedures, such as myelography, may be restricted or not recommended for children under certain ages as noted in the official labeling.
• Comorbidities: Special precautions are necessary for patients with severe cardiovascular disease, pheochromocytoma, or a history of epilepsy. While iohexol is excreted in breast milk, use during lactation is generally considered acceptable, but requires caution.

Omnipaque (iohexol) has documented interactions with certain medicinal products, which require monitoring or adjustment of the treatment plan.

Medication-Specific Interaction Concerns

• Metformin: For patients taking metformin, an iodinated contrast agent like Omnipaque may increase the risk of lactic acidosis due to potential worsening of kidney function. Metformin should be temporarily stopped at the time of, or prior to, injection.
• Radioactive Iodine: Administration of Omnipaque may interfere with the thyroid's ability to take up radioactive iodine (I-131 and I-123), potentially reducing the efficacy of diagnostic and therapeutic procedures for thyroid conditions.
• Corticosteroids: Simultaneous intrathecal (spinal) administration of corticosteroids and Omnipaque is contraindicated (should not be done).

Drug Classes and Procedural Constraints

• Drugs that lower the seizure threshold (including some antidepressants, CNS stimulants, and certain phenothiazine derivatives) should generally be discontinued for a period before and after intrathecal Omnipaque administration to reduce the risk of seizures.
• Beta-Adrenergic Blocking Agents (Beta-Blockers) can lower the threshold for contrast-related reactions and may reduce the effectiveness of epinephrine used to treat severe hypersensitivity reactions.
• Do not mix Omnipaque injection with any other medicines or total nutritional admixtures in the same syringe or intravenous line.

Omnipaque 300 (iohexol) is a non-ionic, iodinated radiographic contrast agent. Its function is based solely on the physical properties of its molecular structure, not on interaction with specific biological targets like receptors or enzymes. The iohexol molecule incorporates three covalently bound iodine atoms within a stable, water-soluble tri-iodinated benzene ring.

Upon administration, the agent distributes within the targeted vascular space or body cavity. When an X-ray beam is introduced, the iodine atoms' high atomic number facilitates a significantly greater rate of photon absorption compared to the low atomic numbers of surrounding soft tissues. This process, known as the photoelectric effect, results in a temporary, localized increase in radiodensity within the area where the iohexol is concentrated. This differential X-ray attenuation establishes a visible positive contrast against the adjacent physiological structures on the detector. After serving its function, iohexol does not undergo metabolism; its systemic physiological consequence is its rapid and complete elimination from the circulation, primarily via unaltered renal glomerular filtration.

How to Use Omnipaque 300: Official Administration Guidelines

Omnipaque 300 (iohexol 300 mgI/mL) is a diagnostic contrast agent used for various imaging procedures. Its administration is defined by specific guidelines to ensure proper procedural execution. The concentration of 300 mgI/mL is chosen based on the level of vascular or cavity enhancement required.

---

Approved Routes of Administration

Established protocols define multiple pathways for administration, which determines the procedure's setting and technique:

• Intravascular: For procedures like Computed Tomography (CT) of the head and body, urography, and angiography.
• Intrathecal: For imaging the central nervous system, such as myelography (lumbar, cervical, or total columnar).
• Oral/Rectal: For radiographic or CT examination of the gastrointestinal (GI) tract.
• Other Cavities: Includes Intraarticular (arthrography) and Body Cavity procedures (e.g., hysterosalpingography).

---

Dosing and Procedural Requirements

Standard procedural guidelines specify that the lowest dose and concentration needed for adequate visualization must be used. Specific dose ranges are tied to the type of imaging performed, not the patient's condition.

Procedure Type	Adult Dose Range (300 mgI/mL)	Procedural Constraint
CT Head/Body (IV)	50 mL to 200 mL (rapid injection)	Total cumulative IV dose must not exceed 290 mL.
Excretory Urography (IV)	0.6 mL/kg to 1.2 mL/kg	Maximum adult dose is 102 mL.
Intrathecal Myelography	6 mL to 10 mL (volume)	Injection must be made slowly over 1 to 2 minutes.

---

Preparation and Frequency

• Preparation: For oral administration, the injection solution must be diluted with a suitable liquid (e.g., water or juice) to a specific lower concentration just prior to use. The solution may be administered at body temperature (37°C) or room temperature.
• Pediatric Use: Dosing for children is typically weight-based (e.g., 1 mL/kg to 2 mL/kg for CT).
• Frequency: The agent is administered as a single, episodic event per procedure. If sequential or repeat intrathecal examinations are required, an interval of at least 48 hours must pass between administrations to allow drug clearance.

Omnipaque 300 (iohexol) has been evaluated in clinical trials and observational studies that examine its primary function as a radiographic contrast agent. Foundational research, which contributes to the broader evidence landscape, examined the agent's properties across various diagnostic procedures, including imaging of the central nervous system, vascular pathways, and urinary system. Findings describe patterns observed in the studies that are related to the agent's ability to provide temporary contrast necessary for visualization. This evidence base for visualization is well-defined.

Modern research was studied for the agent’s comparative profile, primarily through Randomized Controlled Trials (RCTs) and meta-analyses that examined outcomes monitoring physiological strain or stress. These studies focus on the risk of temporary kidney changes (Contrast-Induced Acute Kidney Injury, or CI-AKI), where researchers monitored biomarkers like serum creatinine over short-term intervals. Findings were mixed when evaluating Iohexol against other contrast media classes, meaning comparative evidence remains uncertain across all patient types.

Separately, specialized Pharmacokinetic (PK) studies researched the agent's rapid elimination from the body. These findings indicate patterns in Iohexol elimination related to its role as a marker for estimating GFR (Glomerular Filtration Rate).

However, the evidence base shows that research was observed in studies that typically used limited follow-up durations. Evidence regarding long-term outcomes remains limited. Furthermore, while Iohexol was evaluated in special populations like children and adults with pre-existing conditions, data for certain groups remain insufficient, and subgroup findings are uncertain. Research provides context but not individual predictions.

Key Studies & References OMNIPAQUE (iohexol) injection, solution: FDA Approved Labeling

Common questions about Omnipaque 300 (FAQ)

Q: What is the main difference between Omnipaque 300 and other contrast dyes?

Omnipaque (iohexol) is classified as a non-ionic, low-osmolality contrast agent. This chemical structure, which does not break apart into charged particles in the body, is described in official documents as being different from older ionic agents. This feature allows the solution to have a lower osmolality (a measure of concentration) than some other contrast media.

Q: How long does the Omnipaque 300 stay in your body after the procedure?

Official product information indicates that the drug has a biological half-life of approximately 121 minutes, or about two hours, in adults with normal kidney function. It is designed to be completely eliminated from the body, unmetabolized, primarily through the kidneys, typically within 24 hours after it is administered.

Q: Does drinking extra water help flush Omnipaque 300 out of my system faster?

Adequate hydration both before and after the procedure is described in official information as a way to minimize the risk of temporary changes in kidney function, known as contrast-induced acute kidney injury (CIAKI). The instructions focus on safety and protecting the kidneys, rather than speeding up the agent's natural excretion rate.

Q: Can Omnipaque 300 be used during pregnancy?

Use for the procedure known as hysterosalpingography is strictly contraindicated (must not be used) if pregnancy is known or suspected. For other procedures, official information indicates that the drug should only be used if clearly needed, as insufficient data exists regarding potential risk to the developing fetus.

Q: Why is Omnipaque 300 administered by a healthcare professional only?

The administration of Omnipaque 300 is restricted to healthcare settings because the procedure requires trained personnel and immediate availability of emergency resuscitation equipment. This is necessary to manage potential severe adverse reactions, such as life-threatening anaphylaxis or cardiac events, should they occur.

Q: Is it normal to feel a warm flush after receiving Omnipaque 300?

A warm sensation or feeling of flushing is listed in official adverse reaction data as a reaction that may occur. This is noted particularly following administration into a vein (intravascular use).

Q: How quickly does Omnipaque 300 start to work once injected?

According to official clinical pharmacology, the agent is designed to distribute within the targeted vascular space or body cavity immediately after administration. This rapid action provides the temporary contrast enhancement necessary for imaging.

Q: Are severe allergic reactions to Omnipaque 300 rare or common?

Life-threatening or fatal hypersensitivity reactions (including anaphylaxis) are classified in official documents as serious adverse reactions. Official information notes that known allergies or a previous reaction to contrast media are factors associated with an increased risk.

Q: What are the reported outcomes when Omnipaque 300 is used for angiography?

The drug's function for angiography, which is a specific intra-arterial procedure, is to provide clear visualization of blood vessels. This includes vessels of the heart, aorta, brain (cerebral), and peripheral arteries, allowing for diagnostic assessment.

Q: Does this contrast agent contain preservatives?

The official product description states that the solution for injection is sterile and contains no preservatives. Official guidelines indicate that because no preservatives are included, any unused portion of the product remaining after a single use should be discarded.

Q: Is Omnipaque 300 approved for use in all types of body imaging?

The drug is not approved for all types of medical imaging, but is indicated for specific diagnostic procedures. This includes intravascular uses (such as CT and urography), intrathecal uses (myelography), and certain oral and body cavity procedures (such as arthrography and hysterosalpingography).

Q: How long after the injection should I expect a reaction to occur?

Official safety information indicates that most severe hypersensitivity reactions develop within 3 minutes of the start of injection, but a reaction can also occur hours later. In rare instances, severe skin reactions (SCAR) have been reported to develop from one hour up to several weeks following administration.

Q: What happens if Omnipaque 300 is accidentally given outside the vein?

Injection site reactions may include expected effects like pain, swelling, warmth, or redness. Regulatory information notes that in rare cases, fluid leakage outside the blood vessel, known as extravasation, can occur, which carries a risk of potential tissue damage.

Q: Can a patient drive immediately after a procedure using Omnipaque 300?

Adverse reactions such as temporary dizziness, vision abnormalities, and even seizures have been reported. The presence of these central nervous system (CNS) effects suggests that a patient may need to consider them before resuming activities like driving.

Q: Are there specific symptoms that require contacting a doctor immediately after receiving Omnipaque 300?

Official warnings describe specific signs of a severe allergic reaction (such as chest tightness, difficulty breathing, or swelling of the face/throat) that require immediate medical attention. This includes signs of potential blood clots, such as sudden severe headache, weakness on one side of the body, or chest pain.

Q: Does having asthma increase the risk of a reaction to Omnipaque 300?

Yes, official prescribing information advises that patients with a history of known allergies, including bronchial asthma, have an increased risk of hypersensitivity reactions to the contrast agent.

Q: Can Omnipaque 300 be used if I have diabetes?

Special precaution is required for patients taking the common diabetes medication Metformin. Regulatory documents indicate that Metformin must be temporarily stopped around the time of the procedure due to the increased risk of a serious condition called lactic acidosis, which is linked to temporary kidney function changes.

Q: Can Omnipaque 300 interact with blood thinners?

Official drug interaction lists include certain agents that act as blood thinners, such as Apixaban and Warfarin. The regulatory information indicates that this requires careful assessment by a healthcare provider before the procedure.

Q: Does Omnipaque 300 carry a black box warning?

The FDA labeling includes a Warning Box to highlight the critical risks associated with the drug. This specific warning emphasizes the danger of administering the wrong iodine concentration via the spine (intrathecal route), which may cause death, seizures, or coma.

Q: What is the full chemical name for the active ingredient in Omnipaque 300?

The active ingredient is iohexol. Its complete chemical name, as defined by authoritative chemical databases, is: N, N' -bis(2,3 -dihydroxypropyl) -5 -(( 2,3-dihydroxypropyl) aminocarbonyl) -2,4,6 -triiodo- isophthalamide.

Q: What should I tell the doctor before getting Omnipaque 300?

Official warnings and precautions indicate that patients should inform their doctor about any known allergies (especially to contrast agents or asthma), existing kidney problems, severe thyroid conditions, use of Metformin, or a history of the condition homocystinuria (if receiving the spinal injection).

Q: Are there any common over-the-counter medications that interact with Omnipaque 300?

Regulatory sources report potential interactions with certain common over-the-counter (OTC) drugs, including ibuprofen and acetaminophen. Official information indicates that consultation with a healthcare professional regarding all medications and supplements is part of the necessary precautions before the procedure.

Q: Why do some people feel dizzy after the procedure?

Dizziness is listed in official adverse event reports as an uncommon side effect of the agent. It may also be a symptom of a more serious, though rare, allergic or cardiovascular reaction.

Q: Do studies suggest Omnipaque 300 has different safety profiles in the elderly?

Official product information approves iohexol for use in adults of all ages, but advises that certain patient groups require caution. Clinicians are recommended to perform frequent renal function assessments in older adult patients, especially those taking certain medications.

Q: What is the shelf life of Omnipaque 300 before it's opened?

The shelf life of the sealed product is typically mathbf3 years when it is stored according to regulatory requirements. This includes keeping the agent protected from light and stored below 30 C (86 F).

Omnipaque (iohexol) should be stored at or below 30 C (86 F) and protected from light, including secondary X-rays. It is essential not to freeze the solution.

• Storage Temperature: le 30 C (86 F)
• Light Protection: Store in the original outer carton.

Omnipaque in glass vials or bottles may be warmed up to 37 C (98.6 F) for up to three months before use to improve patient tolerance by reducing viscosity. The solution should be visually inspected for discoloration or particulate matter before administration; if either is present, the product must be discarded.

Omnipaque 300 is for single use only, and any unused portion remaining in the container after a procedure must be immediately discarded. Do not dispose of this medication via household waste or wastewater; consult healthcare professionals or pharmacists for local disposal guidelines to protect the environment.